Alexion Pharma (NASDAQ: ALXN), a United States-based pharmaceutical company, has named Camilla Harder Hartvig as its new senior vice president and head of its EMEAC region, it was reported yesterday.

Hartvig will lead the commercial activities of the regional function from Alexion's EMEAC headquarters in Zurich, Switzerland, where she will succeed Christophe Bourdon who recently left the company to pursue a new opportunity.

Hartvig has more than 20 years' experience in the pharmaceutical industry and has worked in a broad range of companies, including AstraZeneca, Novartis and Allergan. Her expertise lies in a range of therapeutic areas such as cardiovascular, diabetes, respiratory, ophthalmology and oncology. She was most recently president, international markets at Glenmark Pharmaceuticals, where she led the commercial organisation across the European, Russian, Asian and Latin American regions.